Compass Therapeutics Inc. (CMPX) - Net Assets
Based on the latest financial reports, Compass Therapeutics Inc. (CMPX) has net assets worth $209.61 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($231.26 Million) and total liabilities ($21.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore CMPX operating cash flow to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $209.61 Million |
| % of Total Assets | 90.64% |
| Annual Growth Rate | N/A |
| 5-Year Change | 213.51% |
| 10-Year Change | N/A |
| Growth Volatility | 110.81 |
Compass Therapeutics Inc. - Net Assets Trend (2018–2024)
This chart illustrates how Compass Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Compass Therapeutics Inc. for the complete picture of this company's asset base.
Annual Net Assets for Compass Therapeutics Inc. (2018–2024)
The table below shows the annual net assets of Compass Therapeutics Inc. from 2018 to 2024. For live valuation and market cap data, see Compass Therapeutics Inc. (CMPX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $125.23 Million | -15.69% |
| 2023-12-31 | $148.54 Million | -18.22% |
| 2022-12-31 | $181.64 Million | +29.67% |
| 2021-12-31 | $140.08 Million | +250.68% |
| 2020-12-31 | $39.95 Million | +133.68% |
| 2019-12-31 | $-118.60 Million | -39.90% |
| 2018-12-31 | $-84.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Compass Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27751900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.00K | 0.01% |
| Other Comprehensive Income | $210.00K | 0.17% |
| Other Components | $489.69 Million | 391.03% |
| Total Equity | $125.23 Million | 100.00% |
Compass Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Compass Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Smcp SAS
PA:SMCP
|
$403.85 Million |
|
Eik fasteignafélag hf
IC:EIK
|
$403.91 Million |
|
Vox Royalty Corp.
TO:VOXR
|
$403.97 Million |
|
Okea ASA
OL:OKEA
|
$404.02 Million |
|
Shih Her Technologies
TWO:3551
|
$403.60 Million |
|
Shihlin Paper Corp
TW:1903
|
$403.49 Million |
|
Stack Capital Group Inc
TO:STCK
|
$403.32 Million |
|
Jiang Su New Technology Co. Ltd.
SHE:301229
|
$403.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Compass Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 148,538,000 to 125,232,000, a change of -23,306,000 (-15.7%).
- Net loss of 49,375,000 reduced equity.
- New share issuances of 18,113,000 increased equity.
- Other comprehensive income increased equity by 173,000.
- Other factors increased equity by 7,783,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-49.38 Million | -39.43% |
| Share Issuances | $18.11 Million | +14.46% |
| Other Comprehensive Income | $173.00K | +0.14% |
| Other Changes | $7.78 Million | +6.21% |
| Total Change | $- | -15.69% |
Book Value vs Market Value Analysis
This analysis compares Compass Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.49x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-16.95 | $2.27 | x |
| 2019-12-31 | $-2.28 | $2.27 | x |
| 2020-12-31 | $0.71 | $2.27 | x |
| 2021-12-31 | $2.23 | $2.27 | x |
| 2022-12-31 | $1.73 | $2.27 | x |
| 2023-12-31 | $1.17 | $2.27 | x |
| 2024-12-31 | $0.91 | $2.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Compass Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -39.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5808.82%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.12x
- Recent ROE (-39.43%) is below the historical average (-31.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.81 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.88 Million |
| 2020 | -73.85% | 0.00% | 0.00x | 1.30x | $-33.49 Million |
| 2021 | -58.67% | 0.00% | 0.00x | 1.10x | $-96.19 Million |
| 2022 | -21.60% | 0.00% | 0.00x | 1.10x | $-57.39 Million |
| 2023 | -28.61% | 0.00% | 0.00x | 1.06x | $-57.35 Million |
| 2024 | -39.43% | -5808.82% | 0.01x | 1.12x | $-61.90 Million |
Industry Comparison
This section compares Compass Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Compass Therapeutics Inc. (CMPX) | $209.61 Million | 0.00% | 0.10x | $403.75 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways… Read more